NASDAQ:NEPT - Neptune Technologies & Bioressources Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $4.27 +0.06 (+1.43 %) (As of 09/18/2018 04:00 PM ET)Previous Close$4.21Today's Range$4.22 - $4.6352-Week Range$0.80 - $4.75Volume4.98 million shsAverage Volume996,457 shsMarket Capitalization$303.76 millionP/E RatioN/ADividend YieldN/ABeta1.14 Company ProfileDiscussionChartEarnings HistoryFinancialsHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Neptune Technologies & Bioressources Inc., a nutrition products company, produces and commercializes nutraceutical products and turnkey solutions primarily for omega-3 softgel capsules and liquids. It offers specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils, as well as pet supplements. The company's custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Technologies & Bioressources Inc. has an agreement with Tetra Bio-Pharma Inc. for the co-development, commercialization, and marketing of purified cannabinoid oil-based products to address pain and inflammation relief applications for the natural health products and pet veterinary markets. The company was founded in 1925 and is headquartered in Laval, Canada. Receive NEPT News and Ratings via Email Sign-up to receive the latest news and ratings for NEPT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:NEPT CUSIPN/A Webneptunecorp.com Phone45-0687-2262 Debt Debt-to-Equity RatioN/A Current Ratio2.60 Quick Ratio2.08 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$21.56 million Price / Sales15.75 Cash Flow$0.2323 per share Price / Cash18.38 Book Value$0.86 per share Price / Book4.97 Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous EmployeesN/A Outstanding Shares79,520,000Market Cap$303.76 million Neptune Technologies & Bioressources (NASDAQ:NEPT) Frequently Asked Questions What is Neptune Technologies & Bioressources' stock symbol? Neptune Technologies & Bioressources trades on the NASDAQ under the ticker symbol "NEPT." How were Neptune Technologies & Bioressources' earnings last quarter? Neptune Technologies & Bioressources Inc (NASDAQ:NEPT) posted its quarterly earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.04) earnings per share for the quarter. The biotechnology company had revenue of $4.01 million for the quarter. View Neptune Technologies & Bioressources' Earnings History. Who are some of Neptune Technologies & Bioressources' key competitors? Some companies that are related to Neptune Technologies & Bioressources include Intra-Cellular Therapies (ITCI), Omeros (OMER), Retrophin (RTRX), Lexicon Pharmaceuticals (LXRX), Karyopharm Therapeutics (KPTI), Athenex (ATNX), Dicerna Pharmaceuticals (DRNA), Zai Lab (ZLAB), Vanda Pharmaceuticals (VNDA), Apellis Pharmaceuticals (APLS), Rhythm Pharmaceuticals (RYTM), Aptinyx (APTX), Eagle Pharmaceuticals (EGRX), Geron (GERN) and MacroGenics (MGNX). Who are Neptune Technologies & Bioressources' key executives? Neptune Technologies & Bioressources' management team includes the folowing people: Mr. James S. Hamilton, Pres, CEO & DirectorMr. Mario Paradis, VP & CFOMr. Marc Vaugeois, VP of SalesMr. Michel Timperio, Pres of Cannabis Bus.Mr. François-Karl Brouillette, VP of Science & Innovation of Nutraceutical Bus. Has Neptune Technologies & Bioressources been receiving favorable news coverage? News coverage about NEPT stock has trended somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Neptune Technologies & Bioressources earned a news and rumor sentiment score of 0.18 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 46.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for Neptune Technologies & Bioressources. Who are Neptune Technologies & Bioressources' major shareholders? Neptune Technologies & Bioressources' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Alpine Global Management LLC (0.11%) and Bank of Montreal Can (0.05%). Which major investors are selling Neptune Technologies & Bioressources stock? NEPT stock was sold by a variety of institutional investors in the last quarter, including Alpine Global Management LLC. Which major investors are buying Neptune Technologies & Bioressources stock? NEPT stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can. How do I buy shares of Neptune Technologies & Bioressources? Shares of NEPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Neptune Technologies & Bioressources' stock price today? One share of NEPT stock can currently be purchased for approximately $4.27. How big of a company is Neptune Technologies & Bioressources? Neptune Technologies & Bioressources has a market capitalization of $303.76 million and generates $21.56 million in revenue each year. How can I contact Neptune Technologies & Bioressources? Neptune Technologies & Bioressources' mailing address is 545 PROMENADE DU CENTROPOLIS SUITE 100, LAVAL A8, H7T 0A3. The biotechnology company can be reached via phone at 45-0687-2262 or via email at [email protected] MarketBeat Community Rating for Neptune Technologies & Bioressources (NASDAQ NEPT)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 97 (Vote Outperform)Underperform Votes: 71 (Vote Underperform)Total Votes: 168MarketBeat's community ratings are surveys of what our community members think about Neptune Technologies & Bioressources and other stocks. Vote "Outperform" if you believe NEPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEPT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/18/2018 by MarketBeat.com StaffFeatured Article: What is the Dow Jones Industrial Average (DJIA)?